{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:08:26Z","timestamp":1792148906886,"version":"4.4.0"},"reference-count":85,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/mjt.0b013e318249a1b5","type":"journal-article","created":{"date-parts":[[2012,9,8]],"date-time":"2012-09-08T08:27:19Z","timestamp":1347092839000},"page":"222-232","source":"Crossref","is-referenced-by-count":5,"title":["HDL Cholesterol"],"prefix":"10.1097","volume":"21","author":[{"given":"Nitin","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M.","family":"Figueredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-14-20210202","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":". Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Cholesterol Treatment Trialists (CTT) Collaboration.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R2-14-20210202","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":". Effects of torcetrapib in patients at high risk for coronary events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R3-14-20210202","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/0002-9343(51)90183-0","article-title":"Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions.","volume":"11","author":"Barr","year":"1951","journal-title":"Am J Med"},{"key":"R4-14-20210202","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10654-007-9165-7","article-title":"Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.","volume":"22","year":"2007","journal-title":"Eur J Epidemiol"},{"key":"R5-14-20210202","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoproteinthe clinical implications of recent studies.","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"R6-14-20210202","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":". High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"R7-14-20210202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00045415-200201000-00011","article-title":"Genetics and prevention: a new look at high-density lipoprotein cholesterol.","volume":"10","author":"Genest","year":"2002","journal-title":"Cardiol Rev"},{"key":"R8-14-20210202","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-2275(20)39245-2","article-title":". Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins.","volume":"7","author":"Glomset","year":"1966","journal-title":"J Lipid Res"},{"key":"R9-14-20210202","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":". HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R10-14-20210202","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"R11-14-20210202","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1161\/01.ATV.0000184760.95957.d6","article-title":". Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.","volume":"25","author":"Nicholls","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R12-14-20210202","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-14-20210202","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":". Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"R14-14-20210202","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/hc4501.098952","article-title":". Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content.","volume":"104","author":"Rong","year":"2001","journal-title":"Circulation"},{"key":"R15-14-20210202","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":". High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization.","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"R16-14-20210202","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1161\/01.CIR.90.4.1935","article-title":". Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits.","volume":"90","author":"Ameli","year":"1994","journal-title":"Circulation"},{"key":"R17-14-20210202","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","article-title":"Molecular physiology of reverse cholesterol transport.","volume":"36","author":"Fielding","year":"1995","journal-title":"J Lipid Res"},{"key":"R18-14-20210202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1567-5688(02)00041-7","article-title":"Hugh Sinclair lecture: the regulation and remodeling of HDL by plasma factors.","volume":"3","author":"Barter","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"R19-14-20210202","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":". Anti inflammatory properties of HDL.","volume":"95","author":"Barter","year":"2004","journal-title":"Circ Res"},{"key":"R20-14-20210202","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1161\/01.CIR.0000159351.95399.50","article-title":". Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits.","volume":"111","author":"Nicholls","year":"2005","journal-title":"Circulation"},{"key":"R21-14-20210202","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1172\/JCI26206","article-title":". Shotgun proteomics implicates protease inhibition and complement activation in the anti inflammatory properties of HDL.","volume":"117","author":"Vaisar","year":"2007","journal-title":"J Clin Invest"},{"key":"R22-14-20210202","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R23-14-20210202","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":". Statins, high density lipoprotein cholesterol, and regression of coronary atherosclerosis.","volume":"297","author":"Nicholls","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R24-14-20210202","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/030079904125003421","article-title":". Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.","volume":"20","author":"Athyros","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"R25-14-20210202","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":". Fifteen year mortality in coronary drug project patients: long-term benefit with niacin.","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"R26-14-20210202","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin.","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am J Cardiol"},{"key":"R27-14-20210202","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":". Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R28-14-20210202","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":". Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells.","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"R29-14-20210202","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2165\/11203730-000000000-00000","article-title":"Extended-release niacin (nicotinic acid)laropiprant.","volume":"69","author":"Perry","year":"2009","journal-title":"Drugs"},{"key":"R30-14-20210202","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":". Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease.","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R31-14-20210202","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":". Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs high-density lipoprotein cholesterol intervention trial study group.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R32-14-20210202","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":". Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial.","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R33-14-20210202","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.110.960112","article-title":"Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.","volume":"122","author":"Tonkin","year":"2010","journal-title":"Circulation"},{"key":"R34-14-20210202","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":". Action to control cardiovascular risk in diabetes (ACCORD) trial: design and methods.","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"R35-14-20210202","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":". Effect of recombinant apoA-IMilano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.","volume":"290","author":"Nissen","year":"2003","journal-title":"J Am Med Assoc"},{"key":"R37-14-20210202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11883-006-0054-4","article-title":". Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.","volume":"8","author":"Calabresi","year":"2006","journal-title":"Curr Atheroscler Rep"},{"key":"R38-14-20210202","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1021\/bi011716p","article-title":"Apolipoprotein A-IMilano and apolipoprotein A-IParis exhibit an antioxidant activity distinct from that of wildtype apolipoprotein A-I.","volume":"41","author":"Bielicki","year":"2002","journal-title":"Biochemistry"},{"key":"R39-14-20210202","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/01.CIR.97.8.780","article-title":". Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice.","volume":"97","author":"Shah","year":"1998","journal-title":"Circulation"},{"key":"R40-14-20210202","doi-asserted-by":"crossref","first-page":"16307","DOI":"10.1021\/bi991246n","article-title":". Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-I Milano dimer.","volume":"38","author":"Calabresi","year":"1999","journal-title":"Biochemistry"},{"key":"R41-14-20210202","first-page":"144","article-title":"Antiatherogenic small, dense HDLguardian angel of the arterial wall Nat Clin Pract Cardiovasc Med.","volume":"3","author":"Kontush","year":"2006","journal-title":""},{"key":"R42-14-20210202","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":". Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.","volume":"297","author":"Tardif","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R43-14-20210202","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1567-5688(02)00047-8","article-title":"Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL.","volume":"3","author":"Angelin","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"R44-14-20210202","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1161\/01.CIR.0000013424.28206.8F","article-title":". High-density lipoprotein restores endothelial function in hypercholesterolemic men.","volume":"105","author":"Spieker","year":"2002","journal-title":"Circulation"},{"key":"R45-14-20210202","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1161\/01.CIR.0000070934.69310.1A","article-title":". Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein.","volume":"107","author":"Bisoendial","year":"2003","journal-title":"Circulation"},{"issue":"Suppl","key":"R46-14-20210202","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ahj.2004.04.027","article-title":"Focus on high-density lipoproteins in reducing cardiovascular risk.","volume":"148","author":"Brewer","year":"2004","journal-title":"Am Heart J"},{"key":"R47-14-20210202","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S0005-2736(97)00198-3","article-title":". Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles.","volume":"1368","author":"Rodrigueza","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"R48-14-20210202","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1353\/pbm.1984.0031","article-title":"Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle.","volume":"27","author":"Williams","year":"1984","journal-title":"Perspect Biol Med"},{"key":"R49-14-20210202","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/01.CIR.0000089375.60050.35","article-title":". Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-nullmice.","volume":"108","author":"Navab","year":"2003","journal-title":"Circulation"},{"key":"R50-14-20210202","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1161\/01.ATV.0000165694.39518.95","article-title":". Apolipoprotein A-I mimetic peptides.","volume":"25","author":"Navab","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R51-14-20210202","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/ncpcardio0661","article-title":". Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.","volume":"3","author":"Navab","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"R52-14-20210202","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1161\/hc0302.103711","article-title":". Oral administration of an apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol.","volume":"105","author":"Navab","year":"2002","journal-title":"Circulation"},{"key":"R53-14-20210202","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.0000134275.90823.87","article-title":". Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.","volume":"109","author":"Navab","year":"2004","journal-title":"Circulation"},{"issue":"Suppl","key":"R54-14-20210202","first-page":"II","article-title":". Oral administration of the apolipoprotein A-I mimetic peptide D-4F in humans with CHD improves anti-inflammatory function after a single dose.","volume":"114","author":"Bloeden","year":"2006","journal-title":"Circulation"},{"key":"R55-14-20210202","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1194\/jlr.M900151-JLR200","article-title":". An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide.","volume":"50","author":"Wool","year":"2009","journal-title":"J Lipid Res"},{"key":"R56-14-20210202","first-page":"357","article-title":"RVX-208, a stimulator of apolipoprotein AI gene expression for the treatment of cardiovascular diseases.","volume":"11","author":"McNeill","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"R57-14-20210202","first-page":"825","article-title":". RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55:2580-2589.","volume":"56","author":"Bailey","year":"2010","journal-title":"Erratum in: J Am Coll Cardiol"},{"key":"R58-14-20210202","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":". Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R59-14-20210202","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":". Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk.","volume":"299","author":"Thompson","year":"2008","journal-title":"J Am Med Assoc"},{"key":"R60-14-20210202","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":". A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits.","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"R61-14-20210202","first-page":"257","article-title":"The failure of torcetrapib: was it the molecule or the mechanism Arterioscler Thromb Vasc Biol.","volume":"27","author":"Tall","year":"2007","journal-title":""},{"key":"R62-14-20210202","doi-asserted-by":"crossref","first-page":"II","DOI":"10.1161\/circ.116.suppl_16.II_127-b","article-title":". Changes in levels of high-density lipoprotein cholesterol predict the impact of torcetrapib on progression of coronary atherosclerosis: insights from illustrate.","volume":"116","author":"Nicholls","year":"2007","journal-title":"Circulation"},{"key":"R63-14-20210202","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1056\/NEJM199011013231803","article-title":". Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.","volume":"323","author":"Inazu","year":"1990","journal-title":"N Engl J Med"},{"key":"R64-14-20210202","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(97)00093-2","article-title":". Clinical characteristics of double heterozygotes with familial hypercholesterolemia and cholesteryl ester transfer proteindeficiency.","volume":"132","author":"Haraki","year":"1997","journal-title":"Atherosclerosis"},{"key":"R65-14-20210202","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":". Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"R66-14-20210202","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(07)61088-5","article-title":". Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomized, double-blind trial.","volume":"370","author":"Bots","year":"2007","journal-title":"Lancet"},{"key":"R67-14-20210202","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa070635","article-title":". Effect of torcetrapib on the progression of coronary atherosclerosis.","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"R68-14-20210202","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1161\/01.ATV.0000085840.67498.00","article-title":". Administration of tyrosyl radical-oxidized HDL inhibits the development of atherosclerosis in apolipoprotein E-deficient mice.","volume":"23","author":"Macdonald","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R69-14-20210202","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":". Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone.","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R72-14-20210202","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1161\/01.CIR.0000092889.24713.DC","article-title":". Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase.","volume":"108","author":"Maugeais","year":"2003","journal-title":"Circulation"},{"key":"R73-14-20210202","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1172\/JCI16146","article-title":". Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo.","volume":"111","author":"Jin","year":"2003","journal-title":"J Clin Invest"},{"key":"R74-14-20210202","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1371\/journal.pmed.0030022","article-title":". Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis.","volume":"3","author":"Badellino","year":"2006","journal-title":"PLoS Med"},{"key":"R75-14-20210202","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1161\/CIRCULATIONAHA.107.746610","article-title":". Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus.","volume":"117","author":"Davidson","year":"2008","journal-title":"Circulation"},{"key":"R76-14-20210202","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":". Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the periscope randomized controlled trial.","volume":"299","author":"Nissen","year":"2008","journal-title":"J Am Med Assoc"},{"key":"R77-14-20210202","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":". Effects of a potent and selective PPAR- agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.","volume":"297","author":"Nissen","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R78-14-20210202","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.105.560177","article-title":". Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo.","volume":"113","author":"Naik","year":"2006","journal-title":"Circulation"},{"key":"R79-14-20210202","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","article-title":". Synthetic LXR ligand inhibits the development of atherosclerosis in mice.","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R80-14-20210202","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1194\/jlr.R400010-JLR200","article-title":"PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis.","volume":"45","author":"Li","year":"2004","journal-title":"J Lipid Res"},{"key":"R81-14-20210202","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI200421109","article-title":". Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease.","volume":"114","author":"Zheng","year":"2004","journal-title":"J Clin Invest"},{"key":"R82-14-20210202","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nm1637","article-title":". Protein carbamylation links inflammation, smoking, uremia and atherogenesis.","volume":"13","author":"Wang","year":"2007","journal-title":"Nat Med"},{"key":"R83-14-20210202","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.299.11.1265","article-title":". Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.","volume":"299","author":"Bhattacharyya","year":"2008","journal-title":"J Am Med Assoc"},{"key":"R84-14-20210202","first-page":"2199","article-title":"EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches.","volume":"51","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R85-14-20210202","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0021-9150(01)00610-4","article-title":"Increased intra-abdominal fat may lower HDL levels by increasing the fractional catabolic rate of Lp A-I in postmenopausal women.","volume":"160","author":"Vajo","year":"2002","journal-title":"Atherosclerosis"},{"key":"R86-14-20210202","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/ajcn\/79.2.204","article-title":". Effects of moderate-fat (from monounsaturated fat) and low-fat weight-loss diets on the serum lipid profile in overweight and obese men and women.","volume":"79","author":"Pelkman","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"R87-14-20210202","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1161\/01.CIR.102.19.2347","article-title":". Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II.","volume":"102","author":"De Oliveira","year":"2000","journal-title":"Circulation"},{"key":"R88-14-20210202","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0021-9150(78)90149-1","article-title":". Cigarette smoking and HDL cholesterol: the Framingham offspring study.","volume":"30","author":"Garrison","year":"1978","journal-title":"Atherosclerosis"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-201405000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T14:00:36Z","timestamp":1643378436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201405000-00014"}},"subtitle":["All Hope Is Not Lost After the Torcetrapib Setback\u2014Emerging Therapeutic Strategies on the Horizon"],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e318249a1b5","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}